Can the HPV vaccine protect those with a weak immune system?
NCT ID NCT03519464
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the HPV vaccine Gardasil 9 can trigger an immune response in people with idiopathic CD4 T cell lymphocytopenia (ICL), a rare condition that weakens the immune system. About 54 adults with ICL and some healthy volunteers will receive three doses of the vaccine over six months. Researchers will measure antibody levels to see if the vaccine helps protect against HPV-related diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gardasil 9 (HPV vaccine)
What this could lead to
If it works, this could show that the HPV vaccine can protect people with ICL from HPV-related diseases like warts and cancers.
What could go wrong
This is a small, early-phase study with only 54 participants, so results may not apply to everyone. The immune system in ICL is weak, so the vaccine may not work as well as in healthy people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 T CELL LYMPHOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States